VEGFR-1/Flt1-14 active protein

Human VEGFR-1/Flt1-14, soluble

Cat. Num. AAA692285

• Gene Names: FLT1; FLT; FLT-1; VEGFR1; VEGFR-1
• Reactivity: Human
• Purity: > 95% by SDS-PAGE & visualized by Coomassie stain
• Synonyms: VEGFR-1/Flt1-14; Human VEGFR-1/Flt1-14; soluble; soluble vascular endothelial growth factor receptor-1; soluble FLT1; soluble VEGFR-1; sFlt1-14; VEGFR-1/Flt1-14 active protein

• Host: Insect cells
• Reactivity: Human
• Purity/Purification: > 95% by SDS-PAGE & visualized by Coomassie stain
• Form/Format: Lyophilized
• Sequence: SKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPELYTSTSPSSSSSSPLSSSSSSSSSSSS
• Sequence Length: 707

• Application Notes: Optimal dilutions should be determined by each laboratory for each application.
• Buffer: PBS
• Reconstitution: The lyophilized sFlt1-14 is soluble in water and most aqueous buffers. The lyophilized sFlt1-14 should be reconstituted in water to a concentration not lower than 100ng/ml.
• Result by N terminal sequencing: SKLKD
• Biological Activity: The activity of sFlt1-14 was determined by its ability to inhibit the VEGF-A-induced proliferation of HDLECs.
• Preparation and Storage: Lyophilized samples are stable for greater than six months at -20 degree C to -70 degree C. Reconstituted sFlt1-14 should be stored in working aliquots at -70 degree C.; Avoid repeated freeze-thaw cycles!

SDS-PAGE (SDS)

(SDS-PAGE analysis of recombinant human sFlt1-14 produced in insect cells. Sample was loaded in 10% SDS-polyacrylamide gel under reducing condition and stained with Coomassie blue.)

Testing Data

(EGF-A BioLISA using recombinant human soluble Flt1-14 for capturing and various recombinant human VEGF-A isoforms as standard. A Biotin-conjugated rabbit anti-human VEGF-A antibody was used for detection. As expected also mouse VEGF164 binds to sFlt1-14.)

Testing Data

(Inhibition of VEGF165-induced proliferation in HDLECs by sFlt1-14. VEGF165 (10ng/ml) was preincubated with increasing amounts of soluble receptor for 1h respectively and then added to the cells.)

Testing Data

(Flt-1 Sandwich-ELISA using recombinant human sFlt1-14 as standard. Mouse anti-human Flt-1 #EWI (MBS690002) was used as capture antibody, Biotinylated rabbit anti-human Flt-1 was used for detection.)

Related Product Information for VEGFR-1/Flt1-14 active protein

A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

Product Categories/Family for VEGFR-1/Flt1-14 active protein

Recombinant Protein; Soluble Receptors; VEGFR-1/Flt1-14; soluble

NCBI and Uniprot Product Information

• NCBI GI #: 229892220
• NCBI GeneID: 2321
• NCBI Accession #: NP_001153392.1
• NCBI GenBank Nucleotide #: NM_001159920.1
• UniProt Accession #: P17948; O60722; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48; B3FR89; B5A923; F5H5L6
• Molecular Weight: ~105 kDa (Monomer)
• NCBI Official Full Name: vascular endothelial growth factor receptor 1 isoform 2
• NCBI Official Synonym Full Names: fms related tyrosine kinase 1
• NCBI Official Symbol: FLT1
• NCBI Official Synonym Symbols: FLT; FLT-1; VEGFR1; VEGFR-1
• NCBI Protein Information: vascular endothelial growth factor receptor 1
• UniProt Protein Name: Vascular endothelial growth factor receptor 1
• UniProt Gene Name: FLT1
• UniProt Synonym Gene Names: FLT; FRT; VEGFR1; VEGFR-1; FLT-1; FLT
• UniProt Entry Name: VGFR1_HUMAN

Uniprot Description

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.